Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures - PubMed (original) (raw)
. 2021 Feb;17(2):292-298.
doi: 10.1016/j.soard.2020.09.037. Epub 2020 Oct 8.
Affiliations
- PMID: 33153965
- DOI: 10.1016/j.soard.2020.09.037
Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures
Brooks V Udelsman et al. Surg Obes Relat Dis. 2021 Feb.
Abstract
Background: Patients with obesity are at increased risk for nonalcoholic fatty liver disease (NAFLD). The effectiveness of noninvasive screening tests for ruling out advanced fibrosis (stage 3-4) is unknown.
Objectives: To determine the prevalence of advanced fibrosis in patients undergoing routine liver biopsy during bariatric surgery and assess the effectiveness of existing noninvasive risk calculators.
Setting: Academic medical center in the United States.
Methods: Routine liver biopsies were obtained during first-time bariatric surgery (January 2001-December 2017). Patient demographic characteristics, co-morbidities, and preoperative laboratory values were compiled. Sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were compared between 3 noninvasive risk calculators for advanced fibrosis: the fibrosis-4 index, NAFLD fibrosis score, and aminotransferase-to-platelet ratio index (APRI).
Results: Among 2465 patients, the prevalence of advanced fibrosis (stage 3-4) was 3.4%. The mean age was 45.5 years, and the mean body mass index was 46.8. The sensitivity of noninvasive risk calculators ranged from 85% (NAFLD fibrosis score) to 24% (APRI). The NAFLD fibrosis score performed best in screening out advanced fibrosis, with an NPV of 99%. The PPV ranged from 9% to 65%. In this study cohort, the use of the NALFD fibrosis score correctly ruled out advanced fibrosis in 893 (36%) patients, with 13 false negatives.
Conclusions: The prevalence of advanced fibrosis in individuals undergoing routine first-time bariatric procedures is 3.4%. Use of the NALFD fibrosis score can rule out advanced fibrosis in one-third of this population, and guide surgical decision-making.
Keywords: Bariatric surgery; Fibrosis; Nonalcoholic fatty liver disease; Risk calculators.
Copyright © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
Comment in
- Comment on: Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures.
Murr MM. Murr MM. Surg Obes Relat Dis. 2021 May;17(5):e17. doi: 10.1016/j.soard.2021.01.029. Epub 2021 Feb 2. Surg Obes Relat Dis. 2021. PMID: 33678571 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical